KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Liabilities (2018 - 2025)

Takeda Pharmaceutical (TAK) has 8 years of Total Liabilities data on record, last reported at -$45.5 billion in Q1 2025.

  • For Q1 2025, Total Liabilities fell 185.98% year-over-year to -$45.5 billion; the TTM value through Mar 2025 reached -$45.5 billion, down 185.98%, while the annual FY2025 figure was -$45.5 billion, 183.8% down from the prior year.
  • Total Liabilities reached -$45.5 billion in Q1 2025 per TAK's latest filing, down from $52.9 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $73.1 billion in Q1 2021 and bottomed at -$48.0 billion in Q1 2023.
  • Average Total Liabilities over 5 years is $19.4 billion, with a median of $52.9 billion recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 268.31% in 2021, then crashed 185.98% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $73.1 billion in 2021, then fell by 11.75% to $64.5 billion in 2022, then tumbled by 174.49% to -$48.0 billion in 2023, then skyrocketed by 210.06% to $52.9 billion in 2024, then crashed by 185.98% to -$45.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were -$45.5 billion in Q1 2025, $52.9 billion in Q1 2024, and -$48.0 billion in Q1 2023.